Yahoo
NasdaqGS - Delayed Quote USD

Aktis Oncology, Inc. (AKTS)

21.26 -0.82 (-3.71%)
At close: April 24 at 4:00:01 PM EDT
21.26 0.00 (0.00%)
After hours: April 24 at 4:10:04 PM EDT
Trade AKTS on Coinbase
Chart Range Bar
Loading chart for AKTS
  • Previous Close 22.08
  • Open 21.81
  • Bid 21.06 x 200
  • Ask 21.59 x 200
  • Day's Range 21.00 - 23.05
  • 52 Week Range 14.72 - 29.16
  • Volume 267,443
  • Avg. Volume 348,483
  • Market Cap (intraday) 1.175B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.21
  • Earnings Date (est.) May 8, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 32.50

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

www.aktisoncology.com

79

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: AKTS

View More

Performance Overview: AKTS

Trailing total returns as of 4/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AKTS
21.26%
S&P 500 (^GSPC)
4.67%

1-Year Return

AKTS
21.26%
S&P 500 (^GSPC)
30.64%

3-Year Return

AKTS
21.26%
S&P 500 (^GSPC)
73.19%

5-Year Return

AKTS
21.26%
S&P 500 (^GSPC)
71.41%

Earnings Trends: AKTS

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 1.87M
Earnings -15.14M

Q4

FY25

-15M
-10M
-5M
0

Analyst Insights: AKTS

View More

Analyst Price Targets

30.00
32.50 Average
21.26 Current
34.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/31/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 30 -> 33

Statistics: AKTS

View More

Valuation Measures

Annual
As of 4/24/2026
  • Market Cap

    1.18B

  • Enterprise Value

    959.93M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    171.87

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    147.75

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -15.79%

  • Return on Equity (ttm)

    -29.45%

  • Revenue (ttm)

    6.5M

  • Net Income Avi to Common (ttm)

    -63.73M

  • Diluted EPS (ttm)

    -1.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    226.79M

  • Total Debt/Equity (mrq)

    6.17%

  • Levered Free Cash Flow (ttm)

    -36.24M

Compare To: AKTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: AKTS

Fair Value

21.26 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: